Bli medlem
Bli medlem

Du är här


Curasight: Canadian patent application relating to uTRACE[®] is ready for allowance in Canada

The company is a pioneer in the field of exploiting the Positron Emissions Tomography (PET) imaging platform targeting the receptor uPAR, which is a known biomarker of cancer aggressiveness, to be used for improved diagnosis in multiple types of cancer.

Curasight has developed a novel radiopharmaceutical platform (uTRACE®) for improved diagnose, risk stratification and treatment monitoring for cancer patients based on uPAR PET Imaging within different cancer indications.

More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

"The validation of this Canadian patent application has now been officially confirmed by the Canadian Intellectual Property Office. For Curasight this is a major milestone for the further development of uTRACE® and of major strategic importance for our strategy in the North American market" says CEO Ulrich Krasilnikoff.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO Phone: +45 22 83 01 60


This information is such information that Curasight A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on 22 October, 2020.

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology provides improved diagnosis and risk stratification in multiple cancer types.

Författare Curasight

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.